Vivimed Labs Complete Financial Statements
12 Years of Data
2026 - 2015
In FY2026, Vivimed Labs (VIVIMEDLAB) reported revenue ₹18 Cr, net profit ₹-147 Cr and EPS ₹-17.24, with a net profit margin of -816.7%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Vivimed Labs stock price NSE.
Complete Financial Data Export
Profitability Ratios
Net Profit Margin
-816.67%
2026 data
EBITDA Margin
-750.00%
2026 data
Operating Margin
-1169.00%
2026 data
Return on Assets
-19.50%
2026 data
Balance Sheet Ratios
Current Ratio
0.33
2026 data
Equity Ratio
-27.98%
2026 data
Asset Turnover
0.02
2026 data
VIVIMEDLAB Revenue, Net Profit & EBITDA — Year-on-Year Growth
VIVIMEDLAB YoY (Mar 2025 vs Mar 2026) — revenue -40.0%, net profit -2350.0%, EBITDA -6850.0%, expenses +442.9%. View VIVIMEDLAB annual price range for the annual high/low range and current price position.
Revenue Growth
-40.0%
Year-over-Year
Net Profit Growth
-2350.0%
Year-over-Year
EBITDA Growth
-6850.0%
Year-over-Year
Expense Growth
+442.9%
Year-over-Year
Assets Growth
-18.1%
Year-over-Year
Equity Growth
-502.9%
Year-over-Year
Operating Cash Flow Growth
+91.7%
Year-over-Year
Investing Cash Flow Growth
-117.9%
Year-over-Year
Financing Cash Flow Growth
+183.3%
Year-over-Year
VIVIMEDLAB Income Statement — Revenue, EBITDA & Net Profit
Vivimed Labs revenue ₹18 Cr, EBITDA ₹-135 Cr, net profit ₹-147 Cr, EPS ₹-17.24 (2026) — net profit margin -816.7%. Check VIVIMEDLAB market value to track the company's total market size over time.
Periods
₹ Crores
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Sept 2020 | Mar 2020 | Jun 2020 | Dec 2020 | Sept 2019 | Mar 2019 | Jun 2019 | Dec 2019 | Sept 2018 | Mar 2018 | Jun 2018 | Dec 2018 | Sept 2017 | Mar 2017 | Jun 2017 | Dec 2017 | Sept 2016 | Mar 2016 | Jun 2016 | Dec 2016 | Sept 2015 | Mar 2015 | Jun 2015 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18 | 21 | 30 | 22 | 16 | 25 | 46 | 29 | 37 | 36 | 38 | 36 | 42 | 44 | 62 | 50 | 56 | 55 | 41 | 66 | 56 | 224 | 238 | 325 | 282 | 284 | 354 | 346 | 200 | 370 | 289 | 364 | 250 | 283 | 439 | 321 | 303 | 299 | 350 | 369 | 363 | 337 | 356 | 332 | 330 |
| Expenses | 152 | 22 | 28 | 22 | 27 | 25 | 67 | 40 | 36 | 40 | 201 | 36 | 40 | 54 | 62 | 59 | 61 | 65 | 55 | 55 | 64 | 206 | 257 | 276 | 300 | 285 | 327 | 303 | 207 | 314 | 252 | 290 | 207 | 220 | 260 | 252 | 251 | 238 | 299 | 302 | 260 | 278 | 304 | 266 | 271 |
| EBITDA | -135 | -1 | 2 | 0 | -11 | -1 | -21 | -11 | 1 | -4 | -164 | 0 | 1 | -9 | -1 | -9 | -5 | -10 | -15 | 12 | -8 | 17 | -18 | 48 | -18 | -1 | 28 | 42 | -7 | 55 | 37 | 75 | 43 | 63 | 180 | 69 | 52 | 61 | 51 | 67 | 103 | 59 | 52 | 66 | 59 |
| Operating Profit Margin % | -1169.00% | -5.00% | -10.00% | -1.00% | -68.00% | -3.00% | -74.00% | -37.00% | 3.00% | -18.00% | -444.00% | -1.00% | 3.00% | -21.00% | -2.00% | -17.00% | -9.00% | -19.00% | -42.00% | 17.00% | -13.00% | 7.00% | -9.00% | 14.00% | -8.00% | -1.00% | 6.00% | 12.00% | -4.00% | 14.00% | 12.00% | 19.00% | 15.00% | 22.00% | 41.00% | 21.00% | 16.00% | 20.00% | 14.00% | 18.00% | 28.00% | 17.00% | 15.00% | 20.00% | 18.00% |
| Depreciation | 12 | 5 | 6 | 5 | 5 | 4 | 6 | 4 | 7 | 5 | 96 | 5 | 5 | 4 | 5 | 4 | 4 | 4 | 4 | 5 | 4 | 18 | 18 | 17 | 17 | 17 | 16 | 17 | 16 | 20 | 14 | 16 | 15 | 16 | 13 | 13 | 14 | 15 | 15 | 16 | 16 | 16 | 15 | 15 | 15 |
| Interest | 1 | 2 | 2 | 1 | 1 | 0 | -33 | 0 | 1 | 12 | 9 | 11 | 13 | 9 | 10 | 9 | 9 | 9 | 9 | 10 | 12 | 14 | 15 | 15 | 16 | 16 | 13 | 12 | 17 | 18 | 16 | 19 | 18 | 21 | 18 | 24 | 17 | 15 | 25 | 15 | 17 | 19 | 22 | 19 | 19 |
| Profit Before Tax | -147 | -7 | -6 | -6 | -17 | -5 | 7 | -15 | -6 | -20 | -268 | -16 | -17 | -22 | -16 | -22 | -18 | -23 | -28 | -2 | -24 | -14 | -50 | 16 | -50 | -34 | -1 | 13 | -39 | 18 | 6 | 39 | 10 | 26 | 149 | 32 | 21 | 31 | 12 | 36 | 70 | 28 | 16 | 33 | 27 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | -2 | 0 | -1 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 3 | -1 | -7 | -1 | 3 | -7 | 0 | -3 | 11 | -1 | 4 | 42 | 8 | 0 | 5 | -1 | 8 | 19 | 4 | -2 | 9 | 4 |
| Net Profit | -147 | -7 | -6 | -6 | -17 | -5 | 5 | -15 | -6 | -20 | -266 | -16 | -16 | -22 | -18 | -22 | -18 | -23 | -28 | -2 | -24 | -14 | -61 | 13 | -50 | -26 | 0 | 10 | -32 | 18 | 9 | 29 | 11 | 22 | 107 | 24 | 21 | 27 | 13 | 28 | 52 | 24 | 18 | 24 | 23 |
| Earnings Per Share (₹) | -17.24 | -0.88 | -0.68 | -0.66 | -2.00 | -0.62 | 0.63 | -1.84 | -0.72 | -2.40 | -32.08 | -1.88 | -1.94 | -2.66 | -2.21 | -2.68 | -2.20 | -2.81 | -3.31 | -0.28 | -2.86 | -1.64 | -7.34 | 1.55 | -5.98 | -3.18 | 0.00 | 1.22 | -3.87 | 2.21 | 1.08 | 3.45 | 1.31 | 2.69 | 12.96 | 2.90 | 2.53 | 3.31 | 7.78 | 3.37 | 6.38 | 2.95 | 11.08 | 14.92 | 14.20 |
VIVIMEDLAB Balance Sheet — Assets, Liabilities & Shareholders' Equity
VIVIMEDLAB total assets ₹754 Cr, total equity ₹-211 Cr, total liabilities ₹ Cr (2026).
Years
Annual Data
₹ Crores
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 754 | 921 | 951 | 995 | 1,266 | 1,289 | 2,210 | 2,329 | 2,394 | 2,062 | 2,044 | 1,899 |
| Current Assets | 168 | 328 | 343 | 339 | 507 | 529 | 975 | 1,231 | 1,282 | 1,094 | 1,133 | 992 |
| Fixed Assets | 403 | 408 | 418 | 436 | 520 | 502 | 1,045 | 965 | 1,035 | 879 | 814 | 814 |
| Capital Work in Progress | 18 | 17 | 21 | 21 | 40 | 60 | 89 | 122 | 65 | 76 | 94 | 90 |
| Investments | 13 | 169 | 169 | 199 | 199 | 199 | 86 | 3 | 3 | 3 | 0 | 0 |
| Other Assets | 0 | 328 | 344 | 340 | 507 | 529 | 990 | 1,239 | 1,290 | 1,104 | 1,135 | 995 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 516 | 548 | 546 | 532 | 528 | 517 | 605 | 496 | 365 | 510 | 561 | 538 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | -211 | -35 | -6 | 39 | 364 | 432 | 835 | 944 | 1,239 | 734 | 585 | 559 |
| Share Capital | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 16 | 80 | 80 |
| Reserves & Surplus | -227 | -52 | -22 | 23 | 348 | 415 | 493 | 602 | 885 | 718 | 505 | 479 |
VIVIMEDLAB Cash Flow Statement — Operating, Investing & Financing
Vivimed Labs operating cash flow ₹-2 Cr, investing ₹-5 Cr, financing ₹5 Cr, net cash flow ₹-1 Cr (2025).
Periods
₹ Crores
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -2 | -24 | 35 | 28 | 567 | 80 | 422 | 21 | 58 | 154 | 141 |
| Investing Activities | -5 | 28 | -5 | -16 | 404 | -196 | -89 | -164 | -69 | -190 | -107 |
| Financing Activities | 5 | -6 | -34 | -10 | -1,015 | 72 | -338 | 186 | 35 | 41 | -42 |
| Net Cash Flow | -1 | -2 | -3 | 1 | -44 | -44 | -5 | 44 | 25 | 4 | -8 |